PPARG and non-small cell lung carcinoma: However, application of rosiglitazonereduced the growth of the NSCLC A549 cells and potentiated theantiproliferative effects of gefitinib and increased PPARγ and PTEN expression in these cells,indicative of a potential benefit of this drug combination also in cancerpatients.